Thank you so much for making Cardiovascular Business a part of your daily lives in 2022. It was truly a year to remember!

Many of the year’s biggest stories were focused on critical recalls, but the interest in Survivor winner Mike Gabler shows that readers also appreciate news with a happy ending. One key trend in 2022 was the rising influence of cardiac CT as a tool for evaluating patients with suspected coronary artery disease. Look for this to be a topic that only grows more and more important as time goes on. Two other trends we are focused on right now are workflow improvements and advances in heart valve technology. What else should we be covering in 2023 and beyond? Feel free to reach out and let us know.

As always, thank you for reading. I have a feeling 2023 is going to be a special year. - Michael Walter, Editor

A well-known cardiologist who once fully supported COVID-19 vaccines is now saying he thinks they have done more harm than good. Online, as one might expect, people on both sides of this particular debate have been quick to respond. 

Erin D. Michos, MD, co-editor in chief of the American Journal of Preventive Cardiology, discusses gender differences in heart disease presentations.

Patients impacted by this recall are advised to speak with a physician about how to proceed. 

The historic procedure took approximately 30 minutes, and the patient went home that same day. 

The annual rankings from U.S. News are here, with some familiar names making the top of the list. Did your facility make the cut? 

Abusing these supplements, a practice often seen in athletics, can lead to significant health issues. 

Patients face a risk of adverse events if they mistakenly take the wrong medication, according to a new warning from the FDA. 

"A CT-first strategy allows physicians to provide relevant findings without the need for an invasive procedure," one radiologist explained. 

The recall is related to short circuit protection (SCP) alerts that were causing the devices to send reduced-energy electric shocks. There have been 27 customer complaints about the issue so far.

The FDA first announced the detection of high levels of NDMA, a contaminant associated with cancer, in extended-release metformin products back in May 2020. 

The study's authors noted that patients should keep taking their medications as normal. However, they see a definite need for more research in this area.

Gabler, a Texas native, has two decades of experience in the cardiology space, spending the last 11 years with Edwards Lifesciences. He has also previously worked for both Medtronic and Boston Scientific.